Let us analyze if the INDEGENE IPO Good or Bad to Invest?
Share With Friends
INDEGENE IPO Details: Key Facts
- INDEGENE is one of the leading biotech consulting companies in India focused exclusively on the global life sciences industry.
- The unique selling point of this company is a digital-first” commercialization company.
- The company refiled the Draft Red Herring Prospectus (INDEGENE IPO DRHP) on December 14, 2022
- Indegene IPO date: – the IPO is opening on 6th May 2024 to 8th May 2024
- Indegene IPO consists of a fresh issue of Equity Shares aggregating up to ₹760 Crore and an offer for sale of 23,932,732 shares (INR 1,081.76 crore)
- Indegene IPO face value: Rs 2
- Indegene is positioned as a leader in the Everest Group PEAK Matrix Assessment 2024. Which is a prestigious group with well know matrix to determine leaders in this category.
- Strong growth potential for this business in India despite high competition.
- I would invest in the company during the IPO process if the valuation of the company is reasonable.
INDEGENE DRHP filed on December 14, 2022, to float its Initial public offering. According to DRHP, this IPO consists of a fresh issue of Equity Shares aggregating up to ₹760 Crore and an offer for sale of Up to 23,932,732 shares (INR 1,081.76 crore). During the offer for sale, only promoters are selling a part of their stake. No investors are selling during this issue.
The net proceeds from this IPO from the Fresh Issue will be utilized towards the expansion of the company and for the Repayment/prepayment of indebtedness of a subsidiary, ILSL Holdings.
Table of Contents
INDEGENE IPO Details
INDEGENE IPO Date Price GMP and other details
| Indegene IPO Details | Indegene IPO date, Price and other |
| Indegene IPO date | May 6, 2024 to May 8, 2024 |
| Indegene IPO Price band | ₹430 to ₹452 per share |
| IPO date of allotment | May 9, 2024 |
| Refunds Initiation date | May 10, 2024 |
| Credit of Shares to Demat Account | May 13, 2024 |
| Indegene IPO date of listing | May 13, 2024 |
| Total IPO size | ₹ 1,841.76 Crore |
| Fresh Issue | ₹ 760 Crore |
| Offer for Sale | 23,932,732 shares (₹ 1,081.76 crore) |
| Retail (Min lot size) | 1 lot of 33 equity shares Total investment ₹14,916 |
| Retail (Max lot size) | 13 lot of 429 equity shares Total investment ₹193,908 |
| Retail Allocation | Not less than 35% of the Net Issue |
| Indegene share price Face Value | ₹ 2 per share |
| Employee Discount | ₹ 30 per share |
| Indegene share price Listing on | BSE & NSE |
Now the big question is – do you invest in the Indegene IPO? Let us find out details about the company and why you should consider investing in this company.
Also, read SEBI registered research analyst: is it good to take their stock picks?
Also, read 52-week high stocks with strong momentum
| Related Articles to Read |
| Green Hydrogen Stocks JNK India IPO Orient Technologies IPO Analysis GO DIGIT IPO Details BHARTI HEXACOM IPO Good or Bad Best Microcap Stocks Best Smallcap IT Companies |
INDEGENE IPO Good or Bad to Invest?
Indegene is a leading biotech solution provider in India that focuses exclusively on the global life sciences industry. Indegene solutions enable biopharmaceutical, emerging biotech, and medical devices companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, and efficient manner.
The company has a strong relationship with 19 of the 20 largest biopharmaceutical companies in the world by revenue for the Financial Year 2021. More than 70% of the total revenue comes from continuing operations for each of the Financial Years 2022, 2021, and 2020 from these 19 customers. As of June 30, 2022, Indegene had a total of 52 active clients.
Also Read
What are Indegene Solutions
The company solutions span across different stages of the commercialization lifecycle of drugs and medical devices. The solutions can be broadly categorized as below.
- Enterprise Commercial Solutions
- Enterprise Medical Solutions
- Enterprise Clinical Solutions
- Omnichannel Activation solutions
- NEXT Technology Platforms
Enterprise Commercial Solutions and Omnichannel Activation Solutions cater to the commercial functions of life sciences companies. Enterprise Medical Solutions and Enterprise Clinical Solutions cater to their medical and R&D functions.
The Next Technology Platforms help organizations automate the process of life sciences content modularization, metadata generation, content comparison, mapping document lineage, and new content creation.
INDEGENE IPO Financial Strength
The company has reported strong growth in revenue of 71.9% CAGR from Enterprise Commercial Solutions operation, while the growth in revenue from Omnichannel Activation was 51.8% CAGR from FY 2020 to FY 2022.
The number of clients has gone up from 34 in Fiscal year 2020 to 52 active clients by June 2022. The company has been generating an EBITDA margin of around 20% across the years reported.
Indegene IPO Good or Bad
Financial Details
| Parameters (in millions of Indian Rupee) | Ended June 30, 2022 | Ended March 31, 2022 | Ended March 31, 2021 | Ended March 31, 2020 |
|---|---|---|---|---|
| Total number of active clients (Units) | 52 | 46 | 44 | 34 |
| Revenue from operations | 5,209.77 | 16,646.09 | 9,662.74 | 6,429.33 |
| YoY revenue growth from operations | NA | 72.27% | 50.29% | NA |
| Profit/(Loss) after tax for the period | 858.15 | 1,628.18 | 1,856.82 | 496.84 |
| Profit margin (%) | 16.47% | 9.78% | 19.22% | 7.73% |
| EBITDA | 1,270.81 | 2,659.10 | 2,639.65 | 1,039.71 |
| Adjusted EBITDA | 1,270.81 | 3,128.09 | 2,611.76 | 1,471.03 |
| Adjusted EBITDA Margin (%) | 24.39% | 18.79% | 27.03% | 22.88% |
Indegene Segment Revenue
| Parameters (in millions of Indian Rupee) | Ended June 30, 2022 | Ended March 31, 2022 | Ended March 31, 2021 | Ended March 31, 2020 | CAGR(1) (Between the Financial Years 2020-2022) |
|---|---|---|---|---|---|
| Revenue from Enterprise Commercial Solutions | 3,057.91 | 10,161.57 | 5,645.75 | 3,437.66 | 71.93% |
| Revenue from Omnichannel Activation | 609.26 | 1,414.15 | 787.38 | 613.55 | 51.82% |
| Revenue from Enterprise Medical Solutions | 1,302.78 | 4,315.59 | 3,050.08 | 2,378.12 | 34.71% |
| Revenue from others | 239.82 | 754.78 | 179.53 | NA | NA |
Objective Behind the INDEGENE IPO
- The company will not receive any proceeds from the Offer for sale. The promoter of the company will take the net proceeds from the OFS.
- The net proceeds from the Fresh Issue will be utilized as below.
- Repayment/prepayment of indebtedness of a subsidiary, ILSL Holdings
- Funding the capital expenditure requirements of the company and its subsidiary, Indegene, Inc
- Payment of consideration towards the acquisition of additional shares in DT Associates Limited by ILSL
- General corporate purposes
- The company will achieve the benefits of listing the Equity Shares on exchanges.
- This will also enhance the visibility and brand image of the company as well as provide a public market for Equity Shares in India.
INDEGENE IPO review: Do you invest?
- The company is one of the fastest-growing companies in the life science segment of the health care industry.
- The global life sciences operations expenditure is expected to reach ₹14.4 trillion (US$187 billion) in 2025.
- The sales and marketing segment was the largest segment of life sciences operations expenditure is the largest segment occupying 36% of the total life sciences operations expenditure.
- Indegene is well positioned to increase its market share in this segment through Enterprise Commercial Solutions while generating 61.04% of revenue from operations for the Financial Year 2022 from this segment.
- The life science industry needs a lot of expertise to establish itself in the world market with strong clientele.
- The company was established in 1998 and the promoters have strong experience in the area.
- The revenue from the operation has been growing consistently for the last three years from 2020 to 2022.
- Considering the above factors INDEGENE is a strong company to invest in.
- I would like to invest in its IPO both for listing gain and long-term investment.
Also Read
Indegene IPO GMP
| Indegene IPO GMP | IPO Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 30-04-2024 | ₹452 | ₹164 | ₹616 |
| 29-04-2024 | ₹452 | ₹164 | ₹616 |
| ₹ | ₹ | ₹ |
Frequently Asked Questions
When did INDEGENE file DRHP?
INDEGENE filed DRHP to float IPO on December 14, 2022, to float its Initial public offering consisting of fresh issues and OFS. Here is the INDEGENE IPO DRHP for your reference.
When was the Indegene company founded?
Indegene was founded in the year 1998.
Who were the promoters of the Indegene company?
Anand Kiran, Dr Sanjay Parikh, Gaurav Kapoor, Dr Rajesh Nair, and Manish Gupta built Indegene in 1998.
Who is the lead manager ?
The lead manager is KOTAK MAHINDRA CAPITAL COMPANY LIMITED
Who is the registrar of this IPO ?
The registrar of Indegene IPO is LINK INTIME INDIA PRIVATE LIMITED.
What is the head quarter of Indegene?
INDEGENE LIMITED
Aspen Block G4, 3rd Floor, Manyata Embassy Business Park,
Outer Ring Road, Nagawara, Bengaluru 560 045, Karnataka
Phone: +91 80 4674 4567
What is the Indegene IPO date
The Indegene IPO may open for subscription on 6th May 2024 (06-04-2024) to 8th May 2024 (08-05-2024) for retail investors.
What is the Indegene IPO Price
Indegene IPO price is fixed in a range of ₹430 to ₹452 per share.
What is the Indegene IPO listing date
The Indegene IPO listing date is May 13, 2024
More From Across our Website
We endeavor to help you to understand different aspects of a company before you invest. Learn all company insights, news analysis, market intelligence with us.
To know more information about company insights for investment, and business overview of companies for investment, here are some suggested readings on company insights for investment – Green Hydrogen Stocks in India, IREDA Share price Target, Tata Motors Stock Price, Tata Play IPO, Upcoming IPOs, Upcoming SME IPOs, Tesla Stock Price.